LUCD Lucid Diagnostics: שווי פעילות לרווח לפני ריבית, מסים ופחת
The price visualization on GURU.Markets shows that Lucid Diagnostics Inc. (LUCD) has an EV/EBITDA of 0.00, while the business relies on a single diagnostic system and anticipates an expansion in insurance reimbursements. Lucid Diagnostics Inc. (LUCD) is implementing EsoGuard AI technologies to detect gastrointestinal oncology via DNA markers. The standardization of such tests in clinics guarantees a steady client inflow and regular profits from the sale of consumables.
luciddx.com (LUCD) - פילוחי מדדים ודוחות פיננסיים
When screening for issuer reliability, this indicator serves as a filter for asset overvaluation. It correlates the total enterprise value (market capitalization plus net debt) with operating profit before depreciation and amortization, reflecting the actual cost of cash flow generation. For Lucid Diagnostics Inc. (LUCD), given its volatile revenue from cancer tests, this metric reveals the risk of an inflated valuation. By analyzing the EV/EBITDA ratio trajectory, an investor can determine the asset's overheating point.
